Association of Bmi-1 mRNA expression with differentiation, metastasis and prognosis of gastric carcinoma.
- Author:
Kai-hong HUANG
1
;
Jian-hua LIU
;
Xue-xian LI
;
Li-bing SONG
;
Mu-sheng ZENG
Author Information
- Publication Type:Journal Article
- MeSH: Cell Differentiation; genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; genetics; Nuclear Proteins; genetics; Polycomb Repressive Complex 1; Prognosis; Proto-Oncogene Proteins; genetics; RNA, Messenger; genetics; metabolism; Repressor Proteins; genetics; Stomach Neoplasms; diagnosis; genetics; pathology
- From: Journal of Southern Medical University 2007;27(7):973-975
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the association of B cell-specific MLV integration site-1 (Bmi-1) mRNA expression level with the differentiation, metastasis and prognosis of gastric carcinoma.
METHODSTissue specimens were obtained from 42 patients undergoing surgery for gastric carcinomas. Reverse transcriptional PCR (RT-PCR) was performed for amplification of Bmi-1 mRNA from the 42 tumor tissues and matched adjacent normal tissues, and the differential Bmi-1 mRNA expression was analyzed for its association with the clinical manifestations of the patients.
RESULTSBmi-1 mRNA expression was detected in all the gastric carcinoma tissues and normal tissues adjacent to the carcinoma using fluorescence method, and in 29 cases, Bmi-1 mRNA expression was significantly higher in the tumor tissues than in the adjacent tissues. Expression of Bmi-1 mRNA was highly correlated with tumor size, lymph node metastasis and T classification (P<0.05), but not with the patients' gender, age, or tumor differentiation (P>0.05). The survival rate was much lower in patients positive for Bmi-1 mRNA expression than in those without Bmi-1 mRNA expression.
CONCLUSIONSBmi-1 mRNA expression is correlated to differentiation and metastasis of gastric carcinoma and may facilitate its prognostic evaluation. Bmi-1 may serve as a marker for assessing the progression of gastric carcinoma and provide assistance for clinical therapeutic decisions.